Program

Program

Friday, Nov 3
Opening Remark
9:30

9:30-9:35

Masayuki YAMAMOTO

Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization

Keynote Lectures

Chairpersons: Masayuki YAMAMOTO (Tohoku Medical Megabank Organization, Japan)
Thomas W. KENSLER (Fred Hutchinson Cancer Center, USA)

KL-1
9:35

9:35-11:05

Sixth Environmental Stress Symposium on the KEAP1-NRF2 System Regulating the
Molecular Basis of Oxidative Stress Response and Its Perturbation
Masayuki YAMAMOTO

Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization

KL-2
10:20

How Important is NRF2 for the Pharmacodynamic Action of “NRF2 Inducers”?
Thomas W KENSLER1, 2
1

Translational Research Program, Fred Hutchinson Cancer Center, USA,
Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, USA2

Co-sponsored by Chugai Pharmaceutical Co., Ltd.

Break11:05-11:25
Session 1

Molecular Mechanisms of the KEAP1-NRF2 System Function 1

11:25-12:25

Chairperson: Donna D. ZHANG (University of Arizona, USA)

S1-1
11:25

NRF2 Buddy for Transcriptional Activation
Hozumi MOTOHASHI
Tohoku University

S1-2
11:55

Proximity Proteomic Analysis Reveals Mechanisms of KEAP1 Inactivation by
Cysteine Modification and New Connections for NRF2 in Parkinson's Disease
Michael Ben MAJOR

Department of Cell Biology, Washington University in St. Louis School of Medicine, USA

Lunch time & Poster Discussion (ODD number)

12:25-13:55

Session 2

13:55-16:05

Molecular Mechanisms of the KEAP1-NRF2 System Function 2
Chairperson: Donna D. ZHANG (University of Arizona, USA)

S2-1
13:55

Nrf2 depletion in the context of Keap1 loss-of-function leads to mitolysosome
accumulation
Albena T DINKOVA-KOSTOVA1, Sharadha DAYALAN NAIDU1, Plamena R ANGELOVA2,
Andrey Y ABRAMOV2
1Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, UK,
UCL Queen Square Institute of Neurology, Queen Square, UK2－ 16 －

14:35

Cross-talk of GCN1-GCN2 branch of ISR and Nrf2 pathway in environmental stressresponse
Ken ITOH

Department of Stress Response Science, Center for Advanced Medical Science, Hirosaki University Graduate School of
Medicine

S2-3
15:05

Selenium in control of ferroptosis – potential roles and cross-talk between glutathione
peroxidases and thioredoxin reductases
Elias S.J. ARNÉR1, 2
1

Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet,
Department of Selenoprotein Research and The National Tumor Biology Laboratory, National Institute of Oncology,
Hungary
2

S2-4
15:35
P-37

Molecular Basis of Stress Response by the KEAP1-NRF2 System
Takafumi SUZUKI1, 2, Masayuki YAMAMOTO1
1

Department of Biochemistry & Molecular Biology, Tohoku Medical Megabank Orgnization, Tohoku University,
Department of Medical Biochemistry, Tohoku Medical Biochemistry, Tohoku University Graduate School of Medicine

2

Break16:05-16:25
Session 3

Molecular Mechanisms of the KEAP1-NRF2 System Function 3

16:25-18:15

Chairperson: Ken ITOH (Hirosaki University, Japan)

S3-1
16:25

From Antioxidant Defense to Iron Homeostasis: NRF2's Multifaceted Guard Against
Ferroptosis
Donna D ZHANG

University of Arizona

S3-2
16:55

Keap1-Nrf2 pathway in the cancer therapeutic resistance and anti-tumor immunity
Youngtae JEONG1, Byungmoo OH1, Ngoc HOANG2, Jeongmin KIM1, Maximilian DIEHN2
1

Department of New Biology, DGIST, 2Cancer Center, Stanford University

S3-3
17:15

Inhibition of liver fibrosis by Nrf2: antagonism of Nrf2 by TGF-beta

Boushra BATHISH1, Sharadha DAYALAN NAIDU1, Thomas S. DIXON1, Abel ANG1, Dorothy
KISIELEWSKI1, Pingting BIAN1, Tadashi HONDA2, Sourav BANERJEE1, Albena T. DINKOVAKOSTOVA1, John D. HAYES1
1

Division of Cellular Medicine, University of Dundee School of Medicine, 2Department of Chemistry and Institute ofChemical Biology & Drug Discovery, Stony Brook University

S3-4
17:35
P-11

Forced Hepatic Expression of NRF2 or NQO1 Alleviates Hepatic Lipid Accumulationand Hepatocellular Damage in a Lipodystrophy Mouse Model
Nobunao WAKABAYASHI1, Yoko YAGISHITA1, 2, Tanvi JOSHI1, Thomas W KENSLER1
1Fred Hutchinson Cancer Center, 2Division of Endocrinology, Columbia University, USA

S3-5
17:55

Mechanisms underlying Nrf2 activation by non-lethal levels of hydrogen peroxide:roles of glutathione sensor neutral sphingomyelinase2, p38 and ERK MAP kinases
and prolyl cis/trans isomerase Pin1
Tetsuro ISHII

School of Medicine, University of Tsukuba

Welcome Reception @Cafeteria

18:30-－ 17 －

Program

S2-2

Program

Saturday, Nov 4
Session 4

9:00-11:00

The KEAP1-NRF2 System and Cancers 1
Chairperson: Hozumi MOTOHASHI (Tohoku University, Japan)

S4-1
9:00

NRF2 and Cancer Immunity
Anna-Liisa LEVONEN

University of Eastern Finland

S4-2
9:30

Pseudohypoxic stabilization of HIF-1α through direct interaction with NRF2 inhepatocellular carcinoma

Jie ZHENG, Su-Jung KIM, Soma SAEIDI, Seong Hoon KIM, Xizhu FANG, Yanymee N. GUILLENQUISPE, Hoang Kieu Chi NGO, Young-Joon SURH
College of Pharmacy, Seoul National University

S4-3
10:00

Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression
Gina M DENICOLA

Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center, USA

S4-4
10:30

Identifying novel vulnerabilities to sensitise KEAP1 mutant lung adenocarcinoma to
T cell mediated killing
Kate D. SUTHERLAND1, 2
1

Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research,
Department of Medical Biology, The University of Melbourne

2

Break11:00-11:20
Session 5

11:20-12:50

The KEAP1-NRF2 System and Cancers 2
Chairperson: Anna-Liisa LEVEON (University of Eastern Finland, Finland)

S5-1
11:20
P-55

Functional Characterization of CNC-sMAF Heterodimers by the Tethered Dimer
Rescue System
Fumiki KATSUOKA1, 2, Masayuki YAMAMOTO1, 2
1

ToMMo, Tohoku University, 2INGEM, Tohoku University

S5-2
11:40
P-54

Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2mediated immune surveillance
Liam BAIRD

INGEM, Tohoku University

S5-3
12:00

Uncovering Metabolic Bottlenecks in KEAP1-mutant Lung Cancer
Thales PAPAGIANNAKOPOULOSNYU Grossman School of Medicine

S5-4
12:30

NRF3: The NRF2-Related Transcription Factor Responding to Arginine Depletion in
CancerAkira KOBAYASHI

Laboratory for Genetic Code, Graduate School of Life and Medical Sciences, Doshisha University

Lunch time & Poster Discussion (EVEN number)
－ 18 －

12:50-14:20

14:20-15:40

The KEAP1-NRF2 System and Diseases 1
Chairperson: Keiko TAGUCHI (The University of Tokyo, Japan)

S6-1
14:20

NRF1 and NRF2 coordinate osteoclastogenesis and bone remodeling

Zhiyuan LIU1, 2, 3, Jinzhi WU1, 2, 3, Wei SHEN1, 2, 3, Zhe DONG1, 2, 3, Yanshuai WANG1, 2, 3, Gang WANG4,
Chengjie CHEN1, 2, Yiying BIAN1, 2, 3, Shengnan LIU1, 2, 3, Huihui WANG1, 2, 5, Lei ZHANG6, Jingqi FU1, 2, 3,
Masayuki YAMAMOTO7, Qiang ZHANG8, Yuanyuan XU1, 2, 5, Jingbo PI1, 2, 3
1

Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention Ministry of Education (China
Medical University),
2
Key Laboratory of Liaoning Province on Toxic and Biological Effects of Arsenic (China Medical University),
3
Program of Environmental Toxicology, School of Public Health, China Medical University,
4
Experimental and Teaching Center, School of Public Health, China Medical University,
5
Group of Chronic Disease and Environmental Genomics, School of Public Health, China Medical University,
6
Center for Genetic Epidemiology and Genomics, School of Public Health, Medical College of Soochow University, China,
7
Department of Medical Biochemistry, Tohoku University, Japan,
8
Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, USA

S6-2
14:50

New roles of Keap1/Nrf2 signaling in thyroid gland function and thyroid
pathophysiology

Gerasimos SYKIOTIS1, Georgios PSARIAS1, Sheng HUANG1, Dionysios CHARTOUMPEKIS1,
Massimo BONGIOVANNI2, Panos ZIROS1
1Service of Endocrinology, Diabetology & Metabolism; Lausanne University Hospital and University of Lausanne,
Synlab Pathology, Switzerland

2

S6-3
15:20

NRF2 and HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic conditions
Mi-Kyoung KWAK, Steffanus P. HALLISThe Catholic University of Korea, College of Pharmacy

Break15:40-16:00
Session 7

16:00-17:50

The KEAP1-NRF2 System and Diseases 2
Chairperson: John D. HAYES (University of Dundee, UK)

S7-1
16:00

Pharmacology & toxicology of Nrf2 in the liver
Ian COPPLE

Department of Pharmacology & Therapeutics, University of Liverpool, UK

S7-2
16:30

Defining the role of the NRF2 transcription factor in synaptic maintenance in
Alzheimer’s disease
Ana I ROJO1, 2, 3, Daniel CARNICERO-SENABRE1, 2, 3, Mariana A BARATA4,
Cláudia GIUMAS ALMEIDA4, Antonio CUADRADO1, 2, 3
1

Department of Biochemistry and Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC, Faculty of Medicine,
Autonomous University of Madrid, Spain,
2
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED),
3
Instituto de Investigación Sanitaria La Paz (IdiPaz),
4iNOVA4Health, CEDOC, NOVA Medical School, NMS, Universidade Nova de Lisboa, Portugal

S7-3
16:50
P-6

NRF2 in stress, ageing and disease
Ioannis TROUGAKOS

Faculty of Biology, National and Kapodistrian University of Athens－ 19 －

Program

Session 6Program

S7-4
17:10
P-14

S7-5
17:30
P-17

The small MAF transcription factor MAFG is a potent driver of melanoma
Florian A KARRETH, Olga VERA, Michael MARTINEZ, Xiaonan XU

Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute

The efficacy of the novel NRF2 activator CH0924 for acute kidney injury

Masaki HOSHINO1, Yukari YASUI1, Shun MITSUMATA1, Manami IIDA1, Yui SUGAWARA1,
Atsushi KIMBARA1, Yuko ITO2, Hitoshi HAGITA3, Naoshi HORIBA1
1

Research Division, Chugai Pharmaceutical Co., Ltd., Japan,
Translational Research Division, Chugai Pharmaceutical Co., Ltd., Japan,
3
Chugai Research Institute for Medical Science Inc., Japan
2

Round-Table Discussion @ ToMMo atrium－ 20 －

18:15-

Session 8

8:40-10:10

The KEAP1-NRF2 System and Drug Development 1
Chairperson: Antonio CUADRADO (Autonomous University of Madrid, Spain)

S8-1
8:40

Developing therapies to target NRF2
Karen T. LIBY

Department of Medicine, Indiana University School of Medicine

Co-sponsored by Kyowa Kirin Co.,Ltd.

S8-2	Non-Electrophilic NRF2 Activators Promote Wound Healing in Human Keratinocytes
9:20
and Diabetic Mice and Demonstrate Selective Downstream Gene Targeting
Terry W MOORE1, 2, May BARAKAT3, 4, Lin CHEN3, Brian P DAVID1, Junhe SHI3, Angela XU3,
Kornelia J SKOWRON1, Tatum JOHNSON1, Reginald WOODS3, 4, Aparna ANKIREDDY5,
Sekhar P REDDY2, 5, Luisa A DIPIETRO3

1

Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, USA,
University of Illinois Cancer Center, USA,
3
Center for Wound Healing and Tissue Regeneration, University of Illinois Chicago College of Dentistry, USA,
4
Medical Scientist Training Program, University of Illinois College of Medicine, USA,
5
Department of Pediatrics, University of Illinois Chicago College of Medicine, USA
2

S8-3
9:50
P-30

ibSLS database: an integrated database for the exploration of environmental stressresponse during space flight
Akihito OTSUKI1, Yuichi AOKI1, 2, Akira URUNO1, Risa OKADA3, Dai SHIBA3,
Fumiki KATSUOKA1, 4, Kengo KINOSHITA1, 2, 4, Masayuki YAMAMOTO1
1

Tohoku Medical Megabank Organization, Tohoku University,
Graduate School of Information Sciences, Tohoku University,
3
Japanese Experiment Module Utilization Center, Human Spaceflight Technology Directorate, Japan Aerospace
Exploration Agency,
4
Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University
2

Break10:10-10:30
Session 9

The KEAP1-NRF2 System and Drug Development 2

10:30-12:00

Chairperson: Albena T. DINKOVA-KOSTOVA (University of Dundee, UK)

S9-1
10:30
P-28

Nrf2 Activation Improves Experimental Rheumatoid Arthritis

Anqi ZHANG1, 2, Takafumi SUZUKI1, 2, Saki ADACHI2, Eiki YOSHIDA2, Masayuki YAMAMOTO1, 2, 3
1

Departments of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University,
Departments of Medical Biochemistry, Tohoku University Graduate School of Medicine,3
The Advanced Research Center for Innovations in Next-Generation Medicine (INGEM), Tohoku University
2－ 21 －

ProgramSunday, Nov 5

Program

S9-2
10:45
P-9

Pharmacologic and genetic activation of Nrf2 confers anti-fibrotic effects

Sharadha DAYALAN NAIDU1, Ralitsa R. MADSEN2, Iain PHAIR1, Boushra AL-BATHISH1,
Abel D. ANG1, Maureen HIGGINS1, Pingting BIAN1, Dorothy KISIELEWSKI1, Terry W. MOORE3,
W. Christian WIGLEY4, John D. HAYES1, Albena T. DINKOVA-KOSTOVA1, 5
1

Division of Cellular & Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical
School, UK,
2
Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of
Dundee, UK,
3
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, USA,
4
Reata Pharmaceuticals, USA,
5
Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of
Medicine, USA

S9-3
11:00
P-32

S9-4
11:15
P-7

Sexual dimorphism of NRF2 target gene modulation

Aikseng OOI, Ben STANSFIELD, Anandhan ANNADURAI, Jinjing CHEN, Donna D ZHANG
University of Arizona

Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven
Esophageal Hyperplasia

Xiaoxin Luke CHEN1, 2, 5, Chorlada PAIBOONRUNGRUANG1, 2, Zhaohui XIONG1, 2, Kevin P WILLIAMS3,
M Ben MAJOR4
1

Coriell Institute for Medical Research,
Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central
University,
3
Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise, North
Carolina Central University,
4
Department of Cell Biology and Physiology, Department of Otolaryngology, Washington University in St. Louis,
5
Surgical Research Lab, Department of Surgery, Cooper University Health Care
2

S9-5
11:30

Targeting the NRF2/beta-TrCP axis in liver disease

Antonio CUADRADO, Raquel FERNANDEZ-GINES, Ana Isabel ROJO
Department of Biochemistry, Medical College, Autonomous University of Madrid

Closing Remark
12:00

12:00-12:15

Masayuki YAMAMOTO

Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization

Lunch12:15-13:30
Public Lecture “Space & Health” 

13:30-15:00* see page 10 & 11

Excursion Tour “Towards Building the Future of Healthcare”
* see page 12 & 13

－ 22 －

16:00-

Friday, Nov 3
12:25-13:55 Poster presentation (Odd numbers)
Saturday, Nov 4
12:50-14:20 Poster presentation (Even numbers)
P-1

The mechanism of aerobic glycolysis mediated malignant behavior of bladderepithelial cells induced by arsenic
Shuhua XI1, 2, 3, Shan Zhu FU1, 2, 3
1

Key Laboratory of Environmental Stress and Chronic Disease Control and Prevention ,Ministry of Education,
Department of Environmental Health, School of Public Health, China Medical University,
3
Key Laboratory of Arsenic Biology and Arsenic Poisoning in Liaoning Province2

P-2

NRF1 facilitates DNA Repair via interaction with PARP1 in protection against lungcarcinogenesis
Yuanyuan XU1, 2, 3, Xin FANG1, 2, 3, Yuxin HU1, 2, 3, Yongfang LI1, 2, 3, Junyi WANG1, 2, 3, Huihui WANG1, 2, 3,
Jingqi FU1, 2, 3, Yongyong HOU1, 2, 3, Jingbo PI1, 2, 3
1School of Public Health, China Medical University,
Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention (China Medical University),
Ministry of Education, 3Key Laboratory of Liaoning Province on Toxic and Biological Effects of Arsenic2

P-3

Pharmacological NRF2 activation by PPI inhibitors: KEAP1- but not NRF2-specific
Miroslav NOVAK1, Sharadha DAYALAN NAIDU1, Dina DIKOVSKAYA1,
Albena T. DINKOVA-KOSTOVA1, 2
1

Division of Cellular Medicine, School of Medicine, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, UK,
Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of
Medicine, USA
2

P-4

Deficiency of Nrf2 exacerbates the osteoclastogenesis and osteoporosis induced byprolonged cadmium exposure: involvement of long isoforms of NRF1 activation
Zhiyuan LIU1, 3, 4, Jinzhi WU1, 3, 4, Zhe DONG1, 3, 4, Yanshuai WANG1, 3, 4, Gang WANG3, 4, 5,
Chengjie CHEN1, 3, 4, Huihui WANG2, 3, 4, Yang YANG6, Yongxi SUN6, Maowei YANG7, Jingqi FU1, 3, 4,
Jiliang LI8, Qiang ZHANG9, Yuanyuan XU2, 3, 4, Jingbo PI1, 3, 4
1

Program of Environmental Toxicology, School of Public Health, China Medical University, China,
Group of Chronic Disease and Environmental Genomics, School of Public Health, China Medical University, China,
3
Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention Ministry of Education (China
Medical University), China,
4
Key Laboratory of Liaoning Province on Toxic and Biological Effects of Arsenic (China Medical University), China,
5
Experimental and Teaching Center, School of Public Health, China Medical University, China,
6
Department of Rehabilitation, The First Affiliated Hospital of China Medical University, China,
7
Department of Orthopedics, The First Affiliated Hospital of China Medical University, China,
8
Department of Biology, Indiana University Purdue University Indianapolis, USA,
9
Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, USA2

P-5

Nrf2 Activation in Atopic Dermatitis

Tomohiro EDAMITSU1, Keiko TAGUCHI1, Eisaku OGAWA2, Ryuhei OKUYAMA2, Masayuki
YAMAMOTO1
1

Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University,
Department of Dermatology, Shinshu University School of Medicine

2

P-6
S7-3

NRF2 in stress, ageing and disease
Ioannis TROUGAKOS

Faculty of Biology, National and Kapodistrian University of Athens－ 23 －

ProgramPoster Session

Program

P-7
S9-4

Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven
Esophageal Hyperplasia

Xiaoxin Luke CHEN1, 2, 5, Chorlada PAIBOONRUNGRUANG1, 2, Zhaohui XIONG1, 2, Kevin P WILLIAMS3,
M Ben MAJOR4
1

Coriell Institute for Medical Research,
Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central
University,
3
Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise, North
Carolina Central University,
4
Department of Cell Biology and Physiology, Department of Otolaryngology, Washington University in St. Louis,
5
Surgical Research Lab, Department of Surgery, Cooper University Health Care2

P-8

The transcription factor NRF1 (NFE2L1) activates aggrephagy by inducing p62 andGABARAPL1 after proteasome inhibition to maintain proteostasis
Atsushi HATANAKA1, Sota NAKADA2, Gen MATSUMOTO3, Katsuya SATOH1, Iori AKETA1,
Akira WATANABE4, Tomoaki HIRAKAWA5, 6, Tadayuki TSUJITA5, 6, Tsuyoshi WAKU2,
Akira KOBAYASHI1, 2
1

Laboratory for Genetic Code, Graduate School of Life and Medical Sciences, Doshisha University,
Laboratory for Genetic Code, Department of Life and Medical Sciences, Doshisha University,
3
Department of Anatomy and Neurobiology, Nagasaki University School of Medicine,
4
Graduate School of Medicine, Kyoto University,
5
Laboratory of Biochemistry, Faculty of Agriculture, Saga University,
6
The United Graduate School of Agricultural Sciences, Kagoshima University
2

P-9
S9-2

Pharmacologic and genetic activation of Nrf2 confers anti-fibrotic effects

Sharadha DAYALAN NAIDU1, Ralitsa R. MADSEN2, Iain PHAIR1, Boushra AL-BATHISH1,
Abel D. ANG1, Maureen HIGGINS1, Pingting BIAN1, Dorothy KISIELEWSKI1, Terry W. MOORE3,
W. Christian WIGLEY4, John D. HAYES1, Albena T. DINKOVA-KOSTOVA1, 5
1

Division of Cellular & Systems Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical
School, UK,
2
Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of
Dundee, UK,
3
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA,
4
Reata Pharmaceuticals, USA,
5
Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of
Medicine, USA

P-10

Mathematical modeling reveals origins of bistability and circadian oscillation ofcellular H2O2 and quantitative properties of KEAP1-NRF2 signaling
Shengnan LIU1, 2, Jingbo PI1, 2, Qiang ZHANG3
1

Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention Ministry of Education, China
Medical University,
2
School of Publich Health, China Medical University,
3
Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University

P-11
S3-4

Forced Hepatic Expression of NRF2 or NQO1 Alleviates Hepatic Lipid Accumulationand Hepatocellular Damage in a Lipodystrophy Mouse Model
Nobunao WAKABAYASHI1, Yoko YAGISHITA1, 2, Tanvi JOSHI1, Thomas W KENSLER1
1Fred Hutchinson Cancer Center, 2Division of Endocrinology, Columbia University, USA

P-12

A tryptophan metabolite, L-Kynurenine, activates Nrf2 in human and mouse
macrophages

Jialin FENG1, Sharadha Dayalan NAIDU1, Oliver READ1, Ying ZHANG1, Albena DINKOVA-KOSTOVA1, 2
1

University of Dundee, 2Johns Hopkins University－ 24 －

6-(methylsulfinyl)hexyl isothiocyanate as a modulator of NRF2 and protector against
tauopathyÁngel Juan GARCíA-YAGüE1, 2, 3, Manuel DEBASA-MOUCE1, 2, 3, Daniel CARNICERO-SENABRE1, 2, 3,
Antonio CUADRADO1, 2, 3
1

Departament of Biochemistry, School of Medicine, Autonomus University of Madrid, UAM, Instituto de Investigaciones
Biomédicas “Alberto Sols” (CSIC-UAM),
2
Instituto de Investigación Sanitaria La Paz (IdiPaz),
3
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)

P-14
S7-4

The small MAF transcription factor MAFG is a potent driver of melanoma
Florian A KARRETH, Olga VERA, Michael MARTINEZ, Xiaonan XU

Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research InstituteP-15

Accelerated mutagenesis of 5’-GAA-3’ sequence in the lung of Nrf2-KO gpt delta mice
Yasunobu AOKI1, Kenichi MASUMURA2, Mizuki OHNO3, Takehiko NOHMI4, Masayuki YAMAMOTO5
1

Health and Environmental Risk Division, National Institute for Environmental Studies, Japan,
Division of Risk Assessment, National Institute of Health Sciences, Japan,
3
Faculty of Medical Sciences, Kyushu University, Japan,
4
Division of Pathology, National Institute of Health Sciences, Japan,
5
Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Japan
2

P-16

Immunological Features of NRF2-Activated Non-Small Cell Lung Cancers

Madoka KAWAGUCHI1, Keito OKAZAKI1, Haruna TAKEDA1, Kento IIDA1, Shigeyuki SHICHINO2,
Kazuki HAYASAKA1, 3, Chikara SAKAI1, 3, Yoshinori OKADA3, Takashi SUZUKI4, Shohei MURAKAMI1,
Hozumi MOTOHASHI1
1

Department of Gene Expression Regulation, Division of Aging Science, Institute of Development, Aging and Cancer,
Tohoku University,
2
Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute of Biomedical Sciences,
Tokyo University of Science, Japan,
3
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Japan,
4
Department of Anatomic Pathology, Tohoku University Graduate School of Medicine, Japan

P-17
S7-5

The efficacy of the novel NRF2 activator CH0924 for acute kidney injury

Masaki HOSHINO1, Yukari YASUI1, Shun MITSUMATA1, Manami IIDA1, Yui SUGAWARA1,
Atsushi KIMBARA1, Yuko ITO2, Hitoshi HAGITA3, Naoshi HORIBA1
1

Research Division, Chugai Pharmaceutical Co., Ltd., Japan,
Translational Research Division, Chugai Pharmaceutical Co., Ltd., Japan,
3
Chugai Research Institute for Medical Science Inc., Japan2

P-18

KEAP1-NRF2 System Mutation Detection by a Splicing Junction Aberration-based
Classifier

Raúl Nicolás MATEOS1, Wira WINARDI2, Ai OKADA1, Naoko IIDA1, Yoshitaka SAKAMOTO1,
Wataru NAKAMURA1, Masahiro SUGAWA1, Kenichi CHIBA1, Yoichiro MITSUISHI2, Yuichi SHIRAISHI1
1Div. Genome Analysis Platform Development, National Cancer Center Japan, Research Institute, Japan,
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine

2

P-19

Design, synthesis and biological evaluation of novel Hsp90 inhibitors with reduced
toxicity.

Russ KITSON1, Chuan-Hsin CHANG3, Rui XIONG3, Donna L. DEHN3, David SIEGEL3, David ROSS3,
Christopher J MOODY2
1

Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Charles University, Czech Republic,
Department of Chemistry, The University of Nottingham, UK,
3
Department of Pharmaceutical Sciences. Colorado University, USA2－ 25 －

ProgramP-13

Program

P-20

Nrf2 Activation and Liver Fibrosis: An Investigation of the Effects of TBE-31 on
CCl4-Induced Liver Injury

Pingting BIAN1, Abel ANG1, Boushra BATHISH1, Dorothy KISIELEWSKI1, Sharadha DAYALAN NAIDU1,
Tadashi HONDA5, Albena T DINKOVA-KOSTOVA 1, Timothy J KENDALL2, Neil C HENDERSON3, 4,John D HAYES1
1

Jacqui Wood Cancer Centre, Division of Cellular Medicine, Ninewells Hospital and Medical School, University of
Dundee, UK,
2
University of Edinburgh Centre for Inflammation Research, Institute for Regeneration and Repair, The University of
Edinburgh, UK,
3
Centre for Inflammation Research, The Queen’s Medical Research Institute, Edinburgh BioQuarter, University of
Edinburgh, UK,
4
MRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, UK,
5
Department of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, USA

P-21

Knockout of KEAP1 in lung cancer cells promotes an immunosuppressive phenotype
Christopher John OCCHIUTO1, Karen T LIBY2
1
2

P-22

Department of Pharmacology and Toxicology, Michigan State University, USA,
Department of Medicine, Indiana University, USA

Unraveling the Mechanisms of Cisplatin Resistance in Nasopharyngeal Carcinoma: A
Focus on NRF2-Mediated Cytoprotection and ErbB Family Dysregulation
Ching-Chuan KUO1, Jang-Yang CHANG1, Ya-Chu TANG1, Chi-Yen CHANG2, Wen-Yu PAN2,
Hsin-Huei CHANG1, Huang-Hui CHEN1, Li-Tzong CHEN2, Her-Shyong SHIAH2, Ko-Jiunn LIU2
1
2

P-23

Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes,
National Institute of Cancer Research, National Health Research Institutes

The NRF2-p97-NRF2 negative feedback loop
Aryatara SHAKYA
University of Arizona

P-24

Functional analysis of NRF2-related factor NRF3 in pancreatic tumor growth andmalignancy

Katsuya SATOH1, Takuto MICHIHARA1, Kohei YAMAMOTO2, Ken SATOH1, Mitsuyo MATUMOTO3,
Kazuhiko IGARASHI3, Tsuyoshi WAKU2, Akira KOBAYASHI1, 2
1

Department of Medical Life System, Doshisha University Graduate School of Life and Medical Science, Japan,
Department of Medical Life System, Doshisha University faculty of Life and Medical Science, Japan,
3
Department of Biochemistry, Tohoku University Graduate School of Medicine, Japan2

P-25	The NRF2-related transcription factor NRF3 protects pancreatic cancer cells fromferroptosis by inducing expression of redox related genes

Tian Yu SHI1, Ayari HATANAKA1, Masaki MINEASE2, Kaito SOGA2, Ken SATO1, Atsushi HATANAKA1,
Katsuya SATOH1, Kohei YAMAMOTO2, Keizo NISHIKAWA2, Tsuyoshi WAKU2, Akira KOBAYASHI1, 2
1
2

P-26

Department of Medical Life System, Graduate School of Life and Medical Sciences, Doshisha University, Japan,
Department of Medical Life System, Faculty of Life and Medical Science, Doshisha University, Japan

Macrophage polarization affects basal and inducible NRF2 signalling
Oliver James READ, Albena DINKOVA-KOSTOVA

Department of Cellular Medicine, University of Dundee School of Medicine, UK

P-27

The roles NRF2 plays in microglia in Alzheimer’s disease
ChingTung CHU, Akira URUNO, Masayuki YAMAMOTO

Department of Biochemistry and Molecular Biology, Tohoku University Tohoku Medical Megabank Organization

P-28
S9-1

Nrf2 Activation Improves Experimental Rheumatoid Arthritis

Anqi ZHANG1, 2, Takafumi SUZUKI1, 2, Saki ADACHI2, Eiki YOSHIDA2, Masayuki YAMAMOTO1, 2, 3
1

Departments of Biochemistry and Molecular Biology, Tohoku Medical-Megabank Organization, Tohoku University,
Departments of Medical Biochemistry, Tohoku University Graduate School of Medicine,3
The Advanced Research Center for Innovations in Next-Generation Medicine (INGEM), Tohoku University
2－ 26 －

The triterpenoid CDDO-Methyl ester decreases tumor burden, alters the tumor
microenvironment, and protects from chemotherapy-induced toxicity in a preclinicalmodel of late-stage lung cancer
Jessica Ann MOERLAND1, Karen T. LIBY2
1

Michigan State University, 2Indiana University School of Medicine

P-30
S8-3

ibSLS database: an integrated database for the exploration of environmental stressresponse during space flight
Akihito OTSUKI1, Yuichi AOKI1, 2, Akira URUNO1, Risa OKADA3, Dai SHIBA3,
Fumiki KATSUOKA1, 4, Kengo KINOSHITA1, 2, 4, Masayuki YAMAMOTO1
1

Tohoku Medical Megabank Organization, Tohoku University,
Graduate School of Information Sciences, Tohoku University,
3
Japanese Experiment Module Utilization Center, Human Spaceflight Technology Directorate, Japan Aerospace
Exploration Agency,
4
Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University2

P-31

Compensatry Activation of Nrf2 in Selenoprotein Deficiency Requires Keap1 Cys226/
Cys613 Residues
Miu SATO1, 2, Nahoko YAGUCHI1, Takafumi SUZUKI1, 2, Masayuki YAMAMOTO2
1

Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Japan,
Department of Biochemistry & Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University, Japan

2

P-32
S9-3

Sexual dimorphism of NRF2 target gene modulation

Aikseng OOI, Ben STANSFIELD, Anandhan ANNADURAI, Jinjing CHEN, Donna D ZHANG
University of Arizona

P-33

Hepatocyte-specific deficiency of Nrf2 alters cholesterol metabolism leading to
mitigated atherosclerosis in ApoE-knockout mice

Jingqi FU1, 2, 3, Junying JIAO1, 2, 3, Ning XU1, 2, 3, Xue HAN1, 2, 3, Lei CHANG6, Jiaxin YU1, 2, 3,
Zhixuan HONG1, 2, 3, Chengjie CHEN1, 2, 3, Huihui WANG1, 2, 4, Qiang ZHANG5, Ping XU6, Yuanyuan XU1, 2, 4,
Jingbo PI1, 2, 3
1

Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention (China Medical University),
Ministry of Education, P.R. China,
2
Key Laboratory of Liaoning Province on Toxic and Biological Effects of Arsenic (China Medical University), P.R. China,
3
Program of Environmental Toxicology, School of Public Health, China Medical University, P.R. China,
4Group of Chronic Disease and Environmental Genomics, School of Public Health, China Medical University, P.R. China,
5Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, USA,
6
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing),
Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences,
Beijing Institute of Lifeomics, P.R. China

P-34

NF-E2-related factor 1 suppresses the expression of a spermine oxidase and the
production of highly reactive acrolein

Tomoaki HIRAKAWA1, 2, Megumi TANIUCHI2, Yoko IGUCHI2, Kiko YOSHITAKE2, Yudai SUETSUGU2,
Takeshi UEMURA3, Tadayuki TSUJITA1, 2
1

The United Graduate School of Agricultural Sciences, Kagoshima University,
Laboratory of Biochemistry, Faculty of Agriculture, Saga University,
3
Faculty of Pharmacy and Pharmaceutical Sciences, Josai University2

P-35

Podocyte-specific Nrf2 deficiency aggravates high-glucose-induced kidney injury in
Akita diabetic mice
Chengjie CHEN1, 2, 3, Zhengsheng ZHOU1, 2, 3, Yang YANG1, 2, 3, Zhiyuan LIU1, 2, 3, Yiying BIAN1, 2, 3,
Zhendi WANG1, 2, 3, Shengnan LIU1, 2, 3, Jingqi FU1, 2, 3, Hua ZHOU4, Qiang ZHANG5, Jingbo PI1, 2, 3
1

Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention Ministry of Education (China
Medical University),
2
Key Laboratory of Liaoning Province on Toxic and Biological Effects of Arsenic (China Medical University), P.R. China,
3
Program of Environmental Toxicology, School of Public Health, China Medical University, P.R. China,
4
Department of Nephrology, The Affiliated Shengjing Hospital, China Medical University, P.R. China,
5Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, USA－ 27 －

ProgramP-29

Program

P-36

The role of Nrf2 in diabetic kidney disease of Akita mice

Akira URUNO1, Yexin LIU1, Ritsumi SAITO1, Daisuke SAIGUSA1, 2, Masayuki YAMAMOTO1
1

Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University,
Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University

2

P-37
S2-4

Molecular Basis of Stress Response by the KEAP1-NRF2 System
Takafumi SUZUKI1, 2, Masayuki YAMAMOTO1
1

Department of Biochemistry & Molecular Biology, Tohoku Medical Megabank Orgnization, Tohoku University,
Department of Medical Biochemistry, Tohoku Medical Biochemistry, Tohoku University Graduate School of Medicine

2

P-38

NRF2 protects against TiO2NP-induced arteriovenous thrombosis
Yiying BIAN1, 2, 3, Jingbo PI1, 2, 3
1

Key Laboratory of Environmental Stress and Chronic Disease Control & Prevention, Ministry of Education (China
Medical University),
2
Key Laboratory of Liaoning Province on Toxic and Biological Effects of Arsenic (China Medical University), P.R. China,
3
Program of Environmental Toxicology, School of Public Health, China Medical University, P.R. China

P-39

Withdrawal

P-40

JAXA Space rodent research II: Space flight habitation and Scientific outcomes
Risa OKADA1, Maki OKADA1, Daisuke KAMIMURA1, Hiroe KOBAYASHI1, Dai SHIBA1,
Satoru TAKAHASHI2, Masayuki YAMAMOTO3, 4
1

JEM Utilization Center, Human Spaceflight Technology Directorate, Japan Aerospace Exploration Agency (JAXA),
Laboratory Animal Resource Center in Transborder Medical Research Center, and Department of Anatomy andEmbryology, Institute of Medicine, University of Tsukuba, 3Tohoku Medical Megabank Organization, Tohoku University,
4
Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University2

P-41

Pulmonary effect of exposure to Fe3O4-PEG-PLGA nanoparticles and the role of
Nrf2

Cai ZONG1, Harue SATO1, Stéphanie DEVINEAU2, Claire MCCORD2, Sahoko ICHIHARA3,
Oliver BROOKES2, Ken ITOH4, Masayuki YAMAMOTO5, Sonja BOLAND2, Armelle BAEZA-SQUIBAN2,
Gaku ICHIHARA1
1

Tokyo University of Science, 2Université de Paris,
Jichi Medical University, 4Hirosaki University, 5Tohoku University

3

P-42

JAXA Space rodent research Ⅰ: Pre-Flight preparation
Maki OKADA, Daisuke KAMIMURA, Dai SHIBAJEM Utilization Center, Human Spaceflight Technology Directorate, Japan Aerospace Exploration Agency

P-43

Squamous cell carcinogenesis elicited by NRF2L30F plus Trp53R172H mutations

Jun TAKAHASHI, Takafumi SUZUKI, Miu SATO, Shuji NITTA, Nahoko YAGUCHI, Tatsuki MUTA,
Masayuki YAMAMOTO
Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization

P-44

Investigation of relationship between GCN1 and NRF1 expression during aging in
aging model mice and siRNA knockdown cells
Sudarma BOGAHAWATHTHA1, 2, Tomoaki KAWAMURA1, Kanade SHIGA1, Goki YAMADA1, 2,
Yo-Ichi NABESHIMA3, Ken ITOH4, Tadayuki TSUJITA1, 2
1

Laboratory of Biochemistry, Department of Applied Biochemistry and Food Science, Faculty of Agriculture, Saga
University, Japan,
2
Department of Applied Life Sciences, Graduate School of Agricultural Sciences, Kagoshima University, Japan,
3
Medical Innovation Center, Graduate School of Medicine Kyoto University, Japan, 4Department of Stress Response
Science, Graduate School of Medicine, Hirosaki University, Japan

P-45

Selenophosphate synthetase 1 (SEPHS1) coordinates NRF2-mediated redox
homeostasis
Md. Morshedul ALAM1, 2, Hiroki SEKINE1, Hozumi MOTOHASHI1
1

Department of Gene Expression Regulation, Institute of Development, Aging and Cancer (IDAC), Tohoku University,
Tokyo Biochemical Research Foundation (TBRF) Fellow, Japan2－ 28 －

Anti-cancer effect of 19-position substituted geldanamycin derivatives depends on
NQO1 protein expression in esophageal squamous cell carcinoma cells
Hiroyuki OSHIKIRI, Keiko TAGUCHI, Liam BAIRD, Masayuki YAMAMOTO

Department of Biochemistry & Molecular Biology, Tohoku Medical Megabank Organization

P-47

Modifying the Genetic Codon Redefines the Expression of RecombinantSelenoproteins in Engineered E. coli Strains, Including an Artificial E. coli Strain
Qing CHENG1, Elias S.J. ARNéR1, 2
1

Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet,
Department of Selenoprotein Research, National Institute of Oncology, Hungary

2

P-48

Overcoming Resistance to KRAS Inhibitors: Insights from Nrf2 activation andtargeting additional mutations
Makiko HAYASHI1, Mariana MANCINI1, 2, Emilia VIGNOGNA3, Sahith RAJALINGAM1,
Thales PAPAGIANNAKOPOULOS1
1

NYU Langone Medical Center, 2University of Campinas, 3New York University

P-49

Leucine 305 and 309 Residues Contribute to the Formation of Two Human NRF2
bands in SDS-PAGE
Young-Sam KEUM

College of Pharmacy, Dongguk University

P-50

Narciclasine Inhibits NRF2 by Targeting WDR43 to Sensitize Cisplatin-induced Cell
Death in A549 Cells
Hai Hoang NGO, Young-Sam KEUM

College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, Korea

P-51

Contribution of NRF2 to cisplatin resistance in head and neck squamous cell
carcinoma
Yuki NAKAYAMA, Keiko TAGUCHI, Masayuki YAMAMOTO

Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University, Japan

P-52

Role of NRF2 in HIF-2α-Mediated Cancer Phenotypes in Renal Carcinoma
Steffanus Pranoto HALLIS1, Mi-Kyoung KWAK1, 2
1

Department of Pharmacy, Graduate School of The Catholic University of Korea, Republic of Korea,
College of Pharmacy, The Catholic University of Korea, Republic of Korea

2

P-53

Nrf2 Dependent/Independent Regulations of the Expression of Selenoprotein P by
Sulforaphane
Xinying YE1, Takashi TOYAMA1, Keiko TAGUCHI2, Masayuki YAMAMOTO2, Yoshiro SAITO1
1

Graduate School of Pharmaceutical Sciences, Tohoku University,
Department of Medical Biochemistry, Tohoku University Graduate School of Medicine

2

P-54
S5-2

Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2mediated immune surveillance
Liam BAIRD

INGEM, Tohoku University

P-55
S5-1

Functional Characterization of CNC-sMAF Heterodimers by the Tethered Dimer
Rescue System
Fumiki KATSUOKA1, 2, Masayuki YAMAMOTO1, 2
1

ToMMo, Tohoku University, 2INGEM, Tohoku University

P-56

Neuroprotective effects of sulforaphane on benzo(a)pyrene-induced neurotoxicity inmice
Yousra Reda ARAFA, Cai ZONG, Akane IKOMA, Gaku ICHIHARA

Department of Occupational and Environmental Health, Tokyo University of Science－ 29 －

ProgramP-46

Program

P-57

Dual role of the Keap1-Nrf2 system in a rat liver cirrhosis model that is influenced byhepatic iron condition
Takeshi IZAWA1, Nanako HAMADA1, Yuri ITO1, Keiko TAGUCHI2, Masayuki YAMAMOTO2,
Mitsuru KUWAMURA1
1

Laboratory of Veterinary Pathology, Osaka Metropolitan University,
Biochemistry & Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University

2

P-58

Characterization of 4NQO-induced mouse tongue cancer cells with different Nrf2
activation levels
Soichiro SEKINE, Shun WAKAMORI, Keiko TAGUCHI, Masayuki YAMAMOTO

Biochemistry & Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University

P-59

Metabolic Reprogramming in Nrf2-driven Proliferation of Normal Rat Hepatocytes
by Lead Nitrate
Keiko TAGUCHI1, Marta Anna KOWALIK2, Marina SERRA2, Andrea CADDEO2,
Elisabetta PULIGA3, 4, Marina BACCI5, Seizo KOSHIBA1, Jin INOUE1, Eiji HISHINUMA1,
Andrea MORANDI5, Silvia GIORDANO3, 4, Andrea PERRA2, Masayuki YAMAMOTO1,
Amedeo COLUMBANO2
1

Tohoku Medical Megabank Organization, Tohoku University, 2Biomedical Sciences, Unit of Oncology and MolecularPathology, University of Cagliari, 3Oncology, University of Torino, 4Candiolo Cancer Institute, FPO-IRCCS, Candiolo,
5
Experimental and Clinical Biomedical Sciences, University of Firenze－ 30 －